Mer­ck touts pos­i­tive PhI­II re­sults for 21-va­lent pneu­mo­coc­cal vac­cine can­di­date

Mer­ck tout­ed pos­i­tive topline re­sults on Thurs­day sug­gest­ing its ex­per­i­men­tal 21-va­lent pneu­mo­coc­cal con­ju­gate vac­cine can­di­date best­ed Pfiz­er’s 20-va­lent shot in a Phase III tri­al.

The New Jer­sey phar­ma gi­ant’s V116 showed “sta­tis­ti­cal­ly sig­nif­i­cant im­mune re­spons­es com­pared to PCV20” in serotypes com­mon to both shots in a Phase III tri­al dubbed STRIDE-3 that en­rolled 2,600 vac­cine-naïve adults, Mer­ck an­nounced. Par­tic­i­pants were as­sessed 30 days af­ter be­ing vac­ci­nat­ed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.